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Nivolumab and pembrolizumab are monoclonal antibod-
ies that block the programmed death-1 receptor (PD-1, 
immune responses. Both are recently approved for use in 
the treatment of metastatic melanoma, and nivolumab as 
well for non-small cell lung cancer.
NAME
Nivolumab (Opdivo) and pembrolizumab (Keytruda)
APPROVED FOR 
Metastatic melanoma (both) and non-small cell lung cancer (nivolumab)
TYPE
Nivolumab | a fully human IgG4 monoclonal antibody
Pembrolizumab | a humanized IgG4 monoclonal antibody 
MOLECULAR TARGETS
PD-1, a surface protein of the immunoglobulin superfamily 
CELLULAR TARGETS
PD-1 is present on T cells, B cells, and macrophages. It is induced 
after T cell activation and plays a co-inhibitory role to negatively 
regulate immune responses upon binding to one of its two ligands, 
PD-L1 or PD-L2.
EFFECTS ON TARGETS
PD-1 blockade is thought to prevent PD-L1 expressed on tumor cells, 
stromal cells, and antigen-presenting cells (APC) from engaging PD-1 
expressed on T cells, leading to more robust T cell activity.
DEVELOPED BY
Nivolumab | Ono Pharmceuticals, Medarex > Bristol Myers Squibb
Pembrolizumab | Organon BioSciences > Schering-Plough > Merck
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